EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies

Yi Zhou, Yan Yu, Linzhi Xie, Liwen Wang, Yuhan Yan, Qian Cheng, Jing Liu, Chang Zhang, Xin Li

Cancer Immunology, Immunotherapy · 18.12.2025 · 75 (1)

DOI: 10.1007/s00262-025-04247-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.12.2025. Verfasst von Yi Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. Hauptthemen laut MEDLINE: Thalidomide, Tumor Microenvironment, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundamental Research Funds for Central Universities of the Central South University, National Natural Science Foundation of China, Beijing Medical and Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, an immunomodulatory drug (IMiD), demonstrates clinical synergy with CAR-T therapy, yet the underlying mechanisms driving this potentiation remain poorly defined. This study aimed to elucidate how pomalidomide enhances CAR-T cell function and remodels the immune microenvironment to overcome therapeutic limitations. METHODS: In vitro assays (CCK-8, LDH, qPCR, ELISA, flow cytometry) and bulk RNA-seq assessed pomalidomide's effects on human CAR-T cells. In vivo efficacy was evaluated in myeloma xenograft models. Single-cell RNA sequencing (scRNA-seq) of PBMCs from a lymphoma patient post-CAR-T/pomalidomide assessed immune microenvironment remodeling. RESULTS: Pomalidomide significantly enhanced CAR-T cell proliferation and cytotoxicity in an activation-dependent manner. It upregulated effector molecules (IL-2, IFN-γ) and chemokines (CXCL9-CXCL11), promoted central memory T cells (Tcm), and induced metabolic reprogramming while reducing exhaustion markers. In xenografts, combination therapy induced tumor regression and extended survival vs. CAR-T alone. scRNA-seq revealed pomalidomide-driven remodeling, characterized by increased T/NK cell proportions/activity and reduced myeloid-derived suppressor cell (MDSC) signatures. CONCLUSIONS: Pomalidomide synergizes with CAR-T by directly enhancing CAR-T function (memory, cytokine/chemokine production, metabolic fitness, and reduced exhaustion) and remodeling the suppressive immune microenvironment (increased cytotoxic effectors, diminished MDSC activity). These findings provide a crucial mechanistic rationale for optimizing pomalidomide-CAR-T combinations in refractory lymphoid malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideTumor MicroenvironmentImmunotherapy, AdoptiveReceptors, Chimeric AntigenMultiple MyelomaLymphomaHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

CAR-T therapyImmune microenvironmentLymphoid malignanciesMemory T cellPomalidomide

Substanzen

pomalidomideThalidomideReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
  • Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. anniezhc@163.com.
  • Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. lixiner1975@163.com.

Förderung

  • Fundamental Research Funds for Central Universities of the Central South University
  • National Natural Science Foundation of China
  • Beijing Medical and Health Foundation

Zitieren

APA

Zhou, Y., Yu, Y., Xie, L., Wang, L., Yan, Y., Cheng, Q., Liu, J., Zhang, C., & Li, X. (2025). Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies. Cancer Immunology, Immunotherapy, 75(1). https://doi.org/10.1007/s00262-025-04247-1

Vancouver

Zhou Y, Yu Y, Xie L, Wang L, Yan Y, Cheng Q, et al. Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies. Cancer Immunology, Immunotherapy. 2025;75(1). doi:10.1007/s00262-025-04247-1

BibTeX
@article{Zhou2025,
  author = {Zhou, Yi and Yu, Yan and Xie, Linzhi and Wang, Liwen and Yan, Yuhan and Cheng, Qian and Liu, Jing and Zhang, Chang and Li, Xin},
  title = {Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {75},
  number = {1},
  doi = {10.1007/s00262-025-04247-1}
}
Kostenlos starten →